




Sydney X. Lu

Assistant Professor of Medicine (Hematology)

Medicine - Hematology

 NIH Biosketch available Online

CLINICAL OFFICE (PRIMARY)

- **Hematology Division**

269 Campus Dr Rm 1155

MC 5156

Stanford, CA 94305

Tel (650) 726-1484 **Fax** (650) 736-0974

Bio

BIO

Sydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.

As a physician, Sydney's group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of 'wet-lab' and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.

Sydney's research is/has been supported by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.

CLINICAL FOCUS

- Hematology

ACADEMIC APPOINTMENTS

- Assistant Professor, Medicine - Hematology
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)

- Faculty Fellow, Sarafan ChEM-H
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Travel Scholarship, American Society for Transplantation and Cellular Therapy (formerly ASBMT) (2006)
- Travel Scholarship, American Society for Transplantation and Cellular Therapy (formerly ASBMT) (2009)
- Abstract Achievement Award, American Society of Hematology (2009)
- Mortimer J. Lacher Fellowship, The Lymphoma Foundation (2017, 2018)
- Loan Repayment Program, National Institutes of Health (2017)
- Abstract Achievement Award, American Society of Hematology (2018)
- Research Award, Aplastic Anemia & Myelodysplastic Syndromes International Foundation (2018)
- Young Investigator Award, Conquer Cancer Foundation (ASCO) (2018)
- Lymphoma Research Fellowship, American Association for Cancer Research-Astrazenaca (2018)
- Portlock Challenge - Robert Hirschhorn Endowment Award, Memorial Sloan Kettering Cancer Center (2019)
- Physician Scientist Fellowship Award (declined), Doris Duke Charitable Foundation (2019)
- Research Training Award for Fellows (declined), American Society of Hematology (2019)
- Career Development Award (Fellow), Leukemia and Lymphoma Society (2019)
- K08 Mentored Clinical Scientist Researcher Career Development Award, NIH/NCI (2020)
- Bridge Scholar, Parker Institute for Cancer Immunotherapy (2020)
- Riney Myeloma Initiative, Paula and Rodger Riney Foundation (2021)
- Clinical Scientist Development Award, Doris Duke Charitable Foundation (2022)
- Scholar Award - Jr. Faculty (basic science/translational), American Society of Hematology (2023)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Sigma Xi (2003 - present)
- Member, American Association of Immunologists (2009 - present)
- Member, American Society of Hematology (2009 - present)
- Member, American Society for Transplantation and Cellular Therapy (formerly ASBMT) (2009 - present)
- Member, American Society for Clinical Oncology (2014 - present)
- Member, American Association for Cancer Research (2017 - present)
- Member, Society for Immunotherapy of Cancer (2021 - present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2020)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2019)
- Fellowship, Memorial Sloan Kettering Cancer Center , Hematology and Medical Oncology (2019)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2016)
- Residency, New York Presbyterian Hospitals, Weill Cornell Campus , Internal Medicine (2015)
- Medical Education: Stanford University School of Medicine (2013) CA
- PhD, Weill Cornell Graduate School of Biomedical Sciences , Immunology (2009)
- BA, Dartmouth College , Chemistry; Biology (2003)

LINKS

- Laboratory website: <https://www.sydneylulab.com/>

Teaching

STANFORD ADVISEES

Doctoral Dissertation Reader (AC)

Camila Bolle, Jada Lauren Garzon, Soyeon Kim, Becca Rodell

Postdoctoral Faculty Sponsor

Agata Sekrecka, Michal Sekrecki

Publications

PUBLICATIONS

- **Novel single cell and bulk NGS assays for improved assessment of MRD (measurable residual disease) and clonal dynamics in acute myeloid leukemia (AML).**
Zhou, C., Gunaratne, R., Yang, E., Agoglia, R., Jangam, D., Tiwari, C., Tanaka, K., Chiang, T., Ho, C., Lu, S., Zehnder, J. L., Zhang, B., Stehr, et al
AMER ASSOC CANCER RESEARCH.2026
- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
2026
- **Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.** *British journal of haematology*
Fakhri, B., Lattupally, R., Sint, K., Stehr, H., Menke, J. R., Conte, M., Shanafelt, T., Lu, S. X.
2025
- **Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16**
Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Cao, X., Chen, V., Zhuang, Z., Dwyer, B., Zhou, C., Tiwari, C., Gabel, A., Kim, W., Stanley, et al
ELSEVIER.2025: 1474-1475
- **Age-related microbiome metabolites alter RNA splicing and chromatin accessibility in the brain.** *bioRxiv : the preprint server for biology*
Chakraborty, M., Shi, S. M., Porter, I. E., Richard, D. J., Marinov, G. K., Moore, A. A., Blum, J. L., Natarajan, A., Jahng, J. W., Wu, J. C., Lu, S. X., Davidson, S. M., Greenleaf, et al
2025
- **Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer.** *Cancer cell*
Rousseau, B., Patel, M., Artz, O., Vlachos, G., Patel, S., Hayatt, O., Argilés, G., Foote, M. B., Luo, L., Shah, R., Mehta, S., Rangavajhula, K., Stewart, et al
2025
- **Chorionic Gonadotropin Beta 7 is a marker of immune evasion in cancer.** *bioRxiv : the preprint server for biology*
McKellar, S. A., Pineda, J. M., Lattupally, R., Codd, A. S., Newell, E. W., Lu, S. X., Bradley, R. K.
2025
- **Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias.** *Cell*
Kim, W. J., Crosse, E. I., De Neef, E., Etxeberria, I., Sabio, E. Y., Wang, E., Bewersdorf, J. P., Lin, K. T., Lu, S. X., Belleville, A., Fox, N., Castro, C., Zhang, et al
2025
- **Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms**
Kim, W., Crosse, E. I., De Neef, E., Etxeberria, I., Sabio, E., Wang, E., Bewersdorf, J., Lu, S. X., Belleville, A., Fox, N., Castro, C., Zhang, P., Fujino, et al
ELSEVIER.2024: 344

- **Steering research on mRNA splicing in cancer towards clinical translation.** *Nature reviews. Cancer*
Anczukow, O., Allain, F. H., Angarola, B. L., Black, D. L., Brooks, A. N., Cheng, C., Conesa, A., Crosse, E. I., Eyra, E., Guccione, E., Lu, S. X., Neugebauer, K. M., Sehgal, et al
2024
- **Evaluating serum free light chain ratio as a biomarker in multiple myeloma.** *Haematologica*
Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Lu, S. X., Patel, D., Shah, U., Tan, C., Derkach, A., Lahoud, O., Landau, et al
2024
- **Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.** *Nature biotechnology*
Zakrzewski, J. L., Suh, D., Markley, J. C., Smith, O. M., King, C., Goldberg, G. L., Jenq, R., Holland, A. M., Grubin, J., Cabrera-Perez, J., Brentjens, R. J., Lu, S. X., Rizzuto, et al
2024
- **Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia.** *Nature cancer*
Knorr, K., Rahman, J., Erickson, C., Wang, E., Monetti, M., Li, Z., Ortiz-Pacheco, J., Jones, A., Lu, S. X., Stanley, R. F., Baez, M., Fox, N., Castro, et al
2023
- **E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.** *Leukemia*
Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., Derkach, A., Wysocki, M., Lu, S. X., Bourcier, J., Hogg, S. J., Rahman, J., Chaudhry, et al
2023
- **Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures.** *Blood*
Diamond, B. T., Ziccheddu, B., Maclachlan, K. H., Taylor, J., Boyle, E. M., Arango Ossa, J. E., Jahn, T. J., Affer, M., Totiger, T. M., Coffey, D. G., Chandhok, N., Watts, J. M., Cimmino, et al
2023
- **Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39**
Bourcier, J., Hogg, S. J., Erickson, C., Singer, M. E., Tittley, S., Ito, T., Egorova, A., Kuttiyara, J., Hanash, A. M., Abdel-Wahab, O., Lu, S. X.
AMER SOC HEMATOLOGY.2022: 1163-1164
- **A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes**
Bewersdorf, J., Stahl, M. F., Taylor, J., Chandhok, N., Watts, J., Derkach, A., Wysocki, M., Kostantakis, V., Lu, S. X., Bourcier, J., Hogg, S., Totiger, T. M., Abdel-Wahab, et al
AMER SOC HEMATOLOGY.2022: 9065-9067
- **Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures**
Ziccheddu, B., Diamond, B., Maclachlan, K. H., Taylor, J., Boyle, E. M., Ossa, J., Jacob, J., Affer, M., Totiger, T. M., Coffey, D., Watts, J., Lu, S. X., Bolli, et al
AMER SOC HEMATOLOGY.2022: 2088-2090
- **Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML**
Knorr, K., Erickson, C., Wang, E., Rahman, J., Mi, X., Lu, S., Fox, N., Penson, A., Hogg, S., Stanley, R., Inoue, D., Knorr, D., Ravetch, et al
AMER SOC HEMATOLOGY.2022: 2247-2248
- **Waldenström Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations.** *Blood advances*
Maclachlan, K. H., Bagratuni, T., Kastritis, E., Ziccheddu, B., Lu, S. X., Yellapantula, V., Famulare, C. A., Argyropoulos, K. V., Derkach, A., Papaemmanuil, E., Dogan, A., Lesokhin, A. M., Usmani, et al
2022
- **Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Shah, U. A., Maclachlan, K. H., Derkach, A., Salcedo, M., Barnett, K., Caple, J., Blaslov, J., Tran, L., Ciardiello, A., Burge, M., Shekarkhand, T., Adintori, P., Cross, et al
2022

- **Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm**
Diamond, B., Ziccheddu, B., Maclachlan, K., Taylor, J., Boyle, E., Coffey, D., Lu, S., Bolli, N., Bolton, K., Park, J., Landau, H., McPherson, A., Sekeres, et al
CIG MEDIA GROUP, LP.2022: S9
- **Evaluating serum free light chain ratio as a biomarker for multiple myeloma**
Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Lu, S., Patel, D., Shah, U., Tan, C., Derkach, A., Lahoud, O., Landau, et al
CIG MEDIA GROUP, LP.2022: S128-S129
- **African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients**
Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A., Hassoun, H., Lu, S., Patel, D., Shah, U., Tan, C., Derkach, A., Lahoud, O., Landau, et al
CIG MEDIA GROUP, LP.2022: S129
- **Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone plus +/- daratumumab induction regimen**
Meseha, M., Abusamra, M., Farooki, A., Derkach, A., Maclachlan, K., Hultcrantz, M., Hassoun, H., Shah, U., Lu, S., Mailankody, S., Patel, D., Lahoud, O., Shah, et al
CIG MEDIA GROUP, LP.2022: S139-S140
- **Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms.**
Diamond, B., Ziccheddu, B., Boyle, E. M., Maclachlan, K., Taylor, J., Watts, J. M., Lu, S. X., Coffey, D. G., Bolli, N., Papaemmanuil, E., Bolton, K., Park, J. H., Landau, et al
AMER ASSOC CANCER RESEARCH.2022
- **Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms**
Diamond, B., Ziccheddu, B., Boyle, E. M., Maclachlan, K., Taylor, J., Watts, J. M., Lu, S. X., Coffey, D. G., Bolli, N., Papaemmanuil, E., Bolton, K., Park, J. H., Landau, et al
AMER ASSOC CANCER RESEARCH.2022
- **African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.**
Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A. M., Hassoun, H., Lu, S. X., Patel, D., Shah, U. A., Tan, C., Derkach, A., Lahoud, O., Landau, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.**
Akhlaghi, T., Maclachlan, K., Korde, N., Mailankody, S., Lesokhin, A. M., Hassoun, H., Lu, S. X., Patel, D., Shah, U. A., Tan, C., Derkach, A., Lahoud, O., Landau, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience.**
Ciardiello, A., Korde, N., Hultcrantz, M., Hassoun, H., Mailankody, S., Shah, U. A., Lu, S. X., Patel, D., Maclachlan, K., Lahoud, O., Shah, G. L., Scordo, M., Chung, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.** *The New England journal of medicine*
Wang, E., Mi, X., Thompson, M. C., Montoya, S., Notti, R. Q., Afaghani, J., Durham, B. H., Penson, A., Witkowski, M. T., Lu, S. X., Bourcier, J., Hogg, S. J., Erickson, et al
2022; 386 (8): 735-743
- **A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study**
Shah, U. A., Alicea, D., Adintori, P. A., Burge, M., Blaslov, J., Derkach, A., Mailankody, S., Korde, N., Tan, C., Hultcrantz, M., Lu, S. X., Patel, D., Hassoun, et al
AMER SOC HEMATOLOGY.2021
- **Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience**
Hultcrantz, M., Orozco, J., Peterson, T. J., Derkach, A., Hassoun, H., Korde, N., Lu, S. X., Mailankody, S., Patel, D., Shah, U. A., Tan, C., Maclachlan, K. H., Chung, et al

AMER SOC HEMATOLOGY.2021

- **The Genomic Landscape of Waldenstrom Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations**
Maclachlan, K. H., Bagratuni, T., Kastritis, E., Ziccheddu, B., Lu, S. X., Yellapantula, V. D., Famulare, C., Diamond, B., Chojnacka, M., Raj, A., Mason, E., Coffey, D. G., Hoffman, et al
AMER SOC HEMATOLOGY.2021
- **Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures**
Shah, U. A., Malik, M., Werner, K., Burge, M., Devlin, S. M., Mailankody, S., Korde, N., Hultcrantz, M., Hassoun, H., Tan, C., Maclachlan, K. H., Lu, S. X., Patel, et al
AMER SOC HEMATOLOGY.2021
- **Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets**
Shah, U., Derkach, A., Adintori, P., Cross, J., Maclachlan, K., Mailankody, S., Korde, N., Hultcrantz, M., Hassoun, H., Tan, C., Lu, S., Patel, D., Shah, et al
CIG MEDIA GROUP, LP.2021: S61
- **Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis** *BRITISH JOURNAL OF HAEMATOLOGY*
Piedra, K., Peterson, T., Tan, C., Orozco, J., Hultcrantz, M., Hassoun, H., Mailankody, S., Lesokhin, A., Shah, U., Lu, S., Patel, D., Derkach, A., Wilkins, et al
2022; 196 (1): 105-109
- **Pharmacologic modulation of RNA splicing enhances anti-tumor immunity** *CELL*
Lu, S. X., De Neef, E., Thomas, J. D., Sabio, E., Rousseau, B., Gigoux, M., Knorr, D. A., Greenbaum, B., Elhanati, Y., Hogg, S. J., Chow, A., Ghosh, A., Xie, et al
2021; 184 (15): 4032-+
- **Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial** *LANCET HAEMATOLOGY*
Diamond, B., Korde, N., Lesokhin, A. M., Smith, E. L., Shah, U., Mailankody, S., Huftcrantz, M., Hassoun, H., Lu, S. X., Tan, C., Rustad, E. H., Maura, F., Maclachlan, et al
2021; 8 (6): E422-E432
- **Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients.**
Hevroni, G., Mastey, D., Tavitian, E., Derkach, A., Salcedo, M., Mailankody, S., Hassoun, H., Lesokhin, A. M., Smith, E. L., Hultcrantz, M., Shah, U. A., Tan, C., Lu, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy** *CLINICA CHIMICA ACTA*
Eveillard, M., Korde, N., Ciardiello, A., Diamond, B., Lesokhin, A., Mailankody, S., Smith, E., Hassoun, H., Hultcrantz, M., Shah, U., Lu, S., Salcedo, M., Werner, et al
2021; 516: 136-141
- **Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial** *JAMA ONCOLOGY*
Landgren, O., Hultcrantz, M., Diamond, B., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C., Shah, U. A., Lu, S. X., Salcedo, M., Werner, K., Rispoli, J., Caple, et al
2021; 7 (6): 862-868
- **Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition** *NATURE GENETICS*
Inoue, D., Polaski, J. T., Taylor, J., Castel, P., Chen, S., Kobayashi, S., Hogg, S. J., Hayashi, Y., Pineda, J., El Marabti, E., Erickson, C., Knorr, K., Fukumoto, et al
2021; 53 (5): 707-+
- **Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m²) in combination with lenalidomide and dexamethasone** *AMERICAN JOURNAL OF HEMATOLOGY*

- Korde, N., Mastey, D., Tavitian, E., Mailankody, S., Lesokhin, A., Hassoun, H., Smith, E. L., Lendvai, N., Hultcrantz, M., Shah, U., Tan, C., Lu, S., Diamond, et al
2021; 96 (6): E193-E196
- **Accelerated single cell seeding in relapsed multiple myeloma (vol 11, 3617, 2020) NATURE COMMUNICATIONS**
Landau, H. J., Yellapantula, V., Diamond, B. T., Rustad, E. H., Maclachlan, K. H., Gundem, G., Medina-Martinez, J., Ossa, J., Levine, M. F., Zhou, Y., Kappagantula, R., Baez, P., Attiyeh, et al
2021; 12 (1): 591
 - **COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers BLOOD CANCER DISCOVERY**
Hultcrantz, M., Richter, J., Rosenbaum, C. A., Patel, D., Smith, E. L., Korde, N., Lu, S. X., Mailankody, S., Shah, U. A., Lesokhin, A. M., Hassoun, H., Tan, C., Maura, et al
2020; 1 (3): 234-243
 - **Accelerated single cell seeding in relapsed multiple myeloma NATURE COMMUNICATIONS**
Landau, H. J., Yellapantula, V., Diamond, B. T., Rustad, E. H., Maclachlan, K. H., Gundem, G., Medina-Martinez, J., Ossa, J., Levine, M. F., Zhou, Y., Kappagantula, R., Baez, P., Attiyeh, et al
2020; 11 (1): 3617
 - **Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma BRITISH JOURNAL OF HAEMATOLOGY**
Eveillard, M., Rustad, E., Roshal, M., Zhang, Y., Ciardiello, A., Korde, N., Hultcrantz, M., Lu, S., Shah, U., Hassoun, H., Smith, E., Lesokhin, A., Mailankody, et al
2020; 189 (5): 904-907
 - **Modern treatments and future directions for newly diagnosed multiple myeloma patients BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY**
Lu, S. X.
2020; 33 (1): 101151
 - **NOVEL ALTERATIONS IN CSF1R, RET, AND OTHER DIVERSE KINASES IN THE HISTIOCYTOSSES WITH BIOCHEMICAL AND STRUCTURAL INSIGHTS INTO THEIR MECHANISMS OF ACTIVATION**
Durham, B., Lopez-Rodrigo, E., Picarsic, J., Abramson, D., Rotemberg, V., De Munck, S., Pannecoucke, E., Lu, S., Pastore, A., Mandelker, D., Birsoy, O., Ulaner, G., Walsh, et al
WILEY.2020: S8-S9
 - **Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms NATURE MEDICINE**
Durham, B. H., Rodrigo, E., Picarsic, J., Abramson, D., Rotemberg, V., De Munck, S., Pannecoucke, E., Lu, S. X., Pastore, A., Yoshimi, A., Mandelker, D., Ceyhan-Birsoy, O., Ulaner, et al
2019; 25 (12): 1839-1842
 - **VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRd) with or without Rivaroxaban Prophylaxis**
Piedra, K. M., Hassoun, H., Buie, L. W., Devlin, S. M., Flynn, J., Hultcrantz, M., Lesokhin, A. M., Lu, S. X., Mailankody, S., Shah, U. A., Smith, E. L., Landgren, O., Korde, et al
AMER SOC HEMATOLOGY.2019
 - **Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study**
Landgren, O., Hultcrantz, M., Lesokhin, A. M., Mailankody, S., Hassoun, H., Smith, E. L., Shah, U. A., Lu, S. X., Mastey, D., Salcedo, M., Diab, V., Werner, K., Rispoli, et al
AMER SOC HEMATOLOGY.2019
 - **Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias**
Inoue, D., Guo-Liang, C., Liu, B., Lee, S. C., Michel, B. C., Pangallo, J., D'Avino, A. R., North, K., Bitner, L. E., Xiao, M., Kobayashi, S., Yoshimi, A., Cho, et al
AMER SOC HEMATOLOGY.2019
 - **Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study**

- Landgren, O., Mastey, D., Lesokhin, A. M., Smith, E. L., Shah, U. A., Mailankody, S., Hultcrantz, M., Hassoun, H., Lu, S. X., Salcedo, M., Diab, V., Werner, K., Rispoli, et al
AMER SOC HEMATOLOGY.2019
- **MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy**
Eveillard, M., Hultcrantz, M., Lesokhin, A. M., Mailankody, S., Smith, E. L., Hassoun, H., Shah, U. A., Lu, S. X., Korde, N., Landgren, O., Thoren, K.
AMER SOC HEMATOLOGY.2019
 - **An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma**
Peterson, T. J., Korde, N., Hassoun, H., Mailankody, S., Lesokhin, A. M., Hultcrantz, M., Shah, U. A., Smith, E. L., Lu, S. X., Landau, H. J., Shah, G. L., Scordo, M., Lahoud, et al
AMER SOC HEMATOLOGY.2019
 - **Spliceosomal disruption of the non-canonical BAF complex in cancer** *NATURE*
Inoue, D., Chew, G., Liu, B., Michel, B. C., Pangallo, J., D'Avino, A. R., Hitchman, T., North, K., Lee, S., Bitner, L., Block, A., Moore, A. R., Yoshimi, et al
2019; 574 (7778): 432-+
 - **Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma** *JAMA ONCOLOGY*
Landgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., Ramanathan, L., Dogan, A., Rustad, et al
2019; 5 (9): 1293-1301
 - **Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL** *NATURE COMMUNICATIONS*
Pastore, A., Gaiti, F., Lu, S. X., Brand, R. M., Kulm, S., Chaligne, R., Gu, H., Huang, K. Y., Stamenova, E. K., Beguelin, W., Jiang, Y., Schulman, R. C., Kim, et al
2019; 10: 1874
 - **Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia** *CANCER CELL*
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., Ki, M., Cho, H., Bitner, et al
2019; 35 (3): 369-+
 - **Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms**
Lu, S. X., Wang, E., Pastore, A., Chen Xufeng, Imig, J., Lee, S. C., Ghebrechristos, Y., Yoshimi, A., Bitner, L. E., Ki, M., Kloetgen, A., Lin, K., Tibes, R., et al
AMER SOC HEMATOLOGY.2018
 - **Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling**
Lee, S. C., North, K., Chen, C., Kim, E., Lu, S. X., Ki, M., Garippa, R., Lowe, S. W., Bradley, R. K., Abdel-Wahab, O. I.
AMER SOC HEMATOLOGY.2018
 - **Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations** *CANCER CELL*
Lee, S., North, K., Kim, E., Jang, E., Obeng, E., Lu, S. X., Liu, B., Inoue, D., Yoshimi, A., Ki, M., Yeo, M., Zhang, X., Kim, et al
2018; 34 (2): 225-+
 - **MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment** *SEMINARS IN HEMATOLOGY*
Landgren, O., Lu, S. X., Hultcrantz, M.
2018; 55 (1): 44-50
 - **Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations** *BLOOD*
Durham, B. H., Getta, B., Dietrich, S., Taylor, J., Won, H., Bogenberger, J. M., Scott, S., Kim, E., Chung, Y., Chung, S. S., Huellein, J., Walther, T., Wang, et al
2017; 130 (14): 1644-1648
 - **Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML** *BLOOD*
Yoshimi, A., Balasis, M. E., Vedder, A., Feldman, K., Ma, Y., Zhang, H., Lee, S., Letson, C., Niyongere, S., Lu, S. X., Ball, M., Taylor, J., Zhang, et al
2017; 130 (4): 397-407

- **Splicing factor SF3B1(K700E) mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1** *PLOS ONE*
Jin, S., Su, H., Ngoc-Tung Tran, Song, J., Lu, S. S., Li, Y., Huang, S., Abdel-Wahab, O., Liu, Y., Zhao, X.
2017; 12 (5): e0175523
- **Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Lu, S. X., Abdel-Wahab, O.
2016; 113 (40): 11071-11073
- **Ceacam1 Separates Graft-versus-Host-Disease from Graft-versus-Tumor Activity after Experimental Allogeneic Bone Marrow Transplantation** *PLOS ONE*
Lu, S. X., Kappel, L. W., Charbonneau-Allard, A., Atallah, R., Holland, A. M., Turbide, C., Hubbard, V. M., Rotolo, J. A., Smith, M., Suh, D., King, C., Rao, U. K., Yim, et al
2011; 6 (7): e21611
- **Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease** *JOURNAL OF IMMUNOLOGY*
Lu, S. X., Holland, A. M., Na, I., Terwey, T. H., Alpdogan, O., Bautista, J. L., Smith, O. M., Suh, D., King, C., Kochman, A., Hubbard, V. M., Rao, U. K., Yim, et al
2010; 185 (3): 1912-1919
- **Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Penack, O., Henke, E., Suh, D., King, C. G., Smith, O. M., Na, I., Holland, A. M., Ghosh, A., Lu, S. X., Jenq, R. R., Liu, C., Murphy, G. F., Lu, et al
2010; 102 (12): 894-908
- **Relapse after Allogeneic Hematopoietic Cell Therapy** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
van den Brink, M. R. M., Porter, D. L., Giralt, S., Lu, S. X., Jenq, R. R., Hanash, A., Bishop, M. R.
2010; 16 (1): S138-S145
- **The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease** *JOURNAL OF CLINICAL INVESTIGATION*
Na, I., Lu, S. X., Yim, N. L., Goldberg, G. L., Tsai, J., Rao, U., Smith, O. M., King, C. G., Suh, D., Hirschhorn-Cymerman, D., Palomba, L., Penack, O., Holland, et al
2010; 120 (1): 343-356
- **NOD2 Regulates Hematopoietic Cell Function During Graft-Versus-Host Disease.**
Penack, O., Smith, O. M., Yim, N., Rao, U., Ghosh, A., Murphy, G. F., Holland, A. M., Jenq, R. R., Lu, S. X., Na, I., van den Brink, M. R. M.
AMER SOC HEMATOLOGY.2009: 967-968
- **TRAIL/DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation**
Na, I., Lu, S. X., Yim, N. L., Goldberg, G. L., Tsai, J., Rao, U. K., Smith, O. M., King, C., Suh, D., Hirschhorn-Cymerman, D., Palomba, M., Penack, O., Holland, et al
AMER SOC HEMATOLOGY.2009: 101
- **Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease** *BLOOD*
Rotolo, J. A., Stancevic, B., Lu, S. X., Zhang, J., Suh, D., King, C. G., Kappel, L. W., Murphy, G. F., Liu, C., Fuks, Z., van den Brink, M. R., Kolesnick, R.
2009; 114 (17): 3693-3706
- **NOD2 regulates hematopoietic cell function during graft-versus-host disease** *JOURNAL OF EXPERIMENTAL MEDICINE*
Penack, O., Smith, O. M., Cunningham-Bussel, A., Liu, X., Rao, U., Yim, N., Na, I., Holland, A. M., Ghosh, A., Lu, S. X., Jenq, R. R., Liu, C., Murphy, et al
2009; 206 (10): 2101-2110
- **The T Cell Cytolytic Molecules FasL and TRAIL are Required for Thymic GVHD**
Lu, S. X., Na, I., Goldberg, G. L., King, C. G., Smith, M., Suh, D., Rao, U., Yim, N., Holland, A. M., Penack, O., Jenq, R. R., Ghosh, A., Houghton, et al
AMER ASSOC IMMUNOLOGISTS.2009

- **NOD2 deficiency in experimental GvHD**
Penack, O., Smith, O., Liu, X., Cunningham, A., Rao, U., Jim, N., Na, I., Holland, A., Ghosh, A., Lu, S., Jenq, R., Ubeda, C., Brandl, et al
NATURE PUBLISHING GROUP.2009: S51
- **Inhibition of vasculogenesis ameliorates GvHD and tumours after allo-BMT**
Penack, O., Henke, E., Suh, D., King, C., Smith, O., Na, I., Holland, A., Ghosh, A., Lu, S., Jenq, R., Liu, C., Murphy, G., Lu, et al
NATURE PUBLISHING GROUP.2009: S20-S21
- **Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation** *BLOOD*
Jenq, R. R., King, C. G., Volk, C., Suh, D., Smith, O. M., Rao, U. K., Yim, N. L., Holland, A. M., Lu, S. X., Zakrzewski, J. L., Goldberg, G. L., Diab, A., Alpdogan, et al
2009; 113 (7): 1574-1580
- **CEACAM1 REGULATES EXPERIMENTAL GRAFT-VERSUS-HOST-DISEASE**
Lu, S. X., Willis, L., Charbonneau-Allard, A. M., Atallah, R., Holland, A. M., Turbide, C., Hubbard, V. M., Rotolo, J. A., Smith, O. M., Suh, D., King, C., Rao, U. K., Yim, et al
ELSEVIER SCIENCE INC.2009: 13
- **DEPLETION OF VASCULAR ENDOTHELIAL PROGENITOR CELLS SIMULTANEOUSLY AMELIORATES GVHD AND INHIBITS TUMOR GROWTH**
Penack, O., Henke, E., Suh, D., King, C., Smith, M., Na, I., Holland, A., Ghosh, A., Lu, S., Feng, R., Liu, C., May, C., Murphy, et al
ELSEVIER SCIENCE INC.2009: 1
- **STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease** *BLOOD*
Lu, S. X., Alpdogan, O., Lin, J., Balderas, R., Campos-Gonzalez, R., Wang, X., Gao, G., Suh, D., King, C., Chow, M., Smith, O. M., Hubbard, V. M., Bautista, et al
2008; 112 (13): 5254-5258
- **Rapidly proliferating CD44(hi) peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation** *BLOOD*
Alpdogan, S., Lu, S. X., Patel, N., McGoldrick, S., Suh, D., Budak-Alpdogan, T., Smith, O. M., Grubin, J., King, C., Goldberg, G. L., Hubbard, V. M., Kochman, A. A., van den Brink, et al
2008; 112 (12): 4755-4764
- **Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation**
Penack, O., Herike, E., Suh, D., King, C., Smith, M. O., Na, I., Holland, A., Ghosh, A., Lu, S. X., Jenq, R., Liu, C., Murphy, G. F., Lu, et al
AMER SOC HEMATOLOGY.2008: 258-259
- **Signal transduction in chronic lymphocytic leukemia (CLL) cells by multiparameter flow-cytometry**
Palomba, M. L., Patel, J. P., Rao, U., Rastalsky, N., Lu, S. X., Houghton, A. N., Zelenetz, A. D., van den Brink, M. R.
ELSEVIER.2008: 192
- **Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors** *NATURE BIOTECHNOLOGY*
Zakrzewski, J. L., Suh, D., Markley, J. C., Smith, O. M., King, C., Goldberg, G. L., Jenq, R., Holland, A. M., Grubin, J., Cabrera-Perez, J., Brentjens, R. J., Lu, S. X., Rizzuto, et al
2008; 26 (4): 453-461
- **Off-the-shelf tumor immunotherapy with genetically enhanced allogeneic T cell precursors**
Zakrzewski, J. L., Suh, D., Markley, J., King, C., Smith, O. M., Goldberg, G., Jenq, R., Holland, A. M., Lu, S., Sant'Angelo, D., Riviere, I., Sadelain, M., van den Brink, et al
FEDERATION AMER SOC EXP BIOL.2008
- **OFF-THE-SHELF TUMOR IMMUNOTHERAPY WITH GENETICALLY ENHANCED ALLOGENEIC T-CELL PRECURSORS**
Zakrzewski, J. L., Suh, D., Markley, J. C., Smith, O. M., King, C., Goldberg, G., Jenq, R., Holland, A. M., Grubin, J., Cabrera-Perez, J., Lu, S. X., Rizzuto, G., Sant'Angelo, et al
ELSEVIER SCIENCE INC.2008: 126
- **Discovery and validation of STAT-3 and ERK1/2 phosphorylation as critical for the function of alloactivated T cells in acute graft-versus-host-disease via a novel technique for drug discovery**
Lu, S. X., Alpdogan, O., Campos, R., Wang, X., Gao, G., Chow, M., Lin, J., Suh, D., King, C., Hubbard, V. M., Bautista, J. L., Kochman, A. A., Zakrzewski, et al

AMER SOC HEMATOLOGY.2007: 950A-951A

● **Targeted 'Off-the-Shelf' tumor immunotherapy using allogeneic T-Cell precursors**

Zakrzewski, J. L., Suh, D., Smith, O. M., King, C., Goldberg, G. L., Jenq, R., Holland, A. M., Grubin, J., Lu, S. X., Cabrera-Perez, J., Rizzuto, G., Sant'Angelo, D. B., van den Brink, et al

AMER SOC HEMATOLOGY.2007: 178A

● **CEACAM-1 is involved in graft-versus-host-disease in murine allogeneic bone marrow transplantation models**

Lu, S. X., Willis, L., Smith, M., Suh, D., King, C., Bautista, J., Chow, M., Cabrera-Perez, J., Hubbard, V., Rotolo, J., Liu, C., Murphy, G., Alpdogan, et al

AMER SOC HEMATOLOGY.2007: 28A

● **IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease** *JOURNAL OF IMMUNOLOGY*

Ramirez-Montagut, T., Chow, A., Kochman, A. A., Smith, O. M., Suh, D., Sindhi, H., Lu, S., Borsotti, C., Grubin, J., Patel, N., Terwey, T. H., Kim, T. D., Heller, et al

2007; 179 (3): 1669-1680

● **Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity** *BLOOD*

Borsotti, C., Franklin, A. R. K., Lu, S. X., Kim, T. D., Smith, O. M., Suh, D., King, C. G., Chow, A., Liu, C., Alpdogan, O., van den Brink, M. R. M.

2007; 110 (2): 783-786

● **Peripheral T cell apoptosis is associated with homeostatic T cell proliferation and plays a significant role in post-transplant immune deficiency.**

Alpdogan, O., Patel, N., Suh, D., Grubin, J., McGoldrick, S., Smith, O. M., Lu, S., King, C., Kochman, A., Hubbard, V., van den Brink, M. R. M.

AMER SOC HEMATOLOGY.2006: 25A

● **Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation** *NATURE MEDICINE*

Zakrzewski, J. L., Kochman, A. A., Lu, S. X., Terwey, T. H., Kim, T. D., Hubbard, V. M., Muriglan, S. J., Suh, D., Smith, O. M., Grubin, J., Patel, N., Chow, A., Cabrera-Perez, et al

2006; 12 (9): 1039-1047

● **Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity** *JOURNAL OF IMMUNOLOGY*

Ramirez-Montagut, T., Chow, A., Hirschhorn-Cymerman, D., Terwey, T. H., Kochman, A. A., Lu, S., Miles, R. C., Sakaguchi, S., Houghton, A. N., van den Brink, M. R. M.

2006; 176 (11): 6434-6442

● **Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration** *BLOOD*

Alpdogan, O., Hubbard, V. M., Smith, O. M., Patel, N., Lu, S., Goldberg, G. L., Gray, D. H., Feinman, J., Kochman, A. A., Eng, J. M., Suh, D., Muriglan, S. J., Boyd, et al

2006; 107 (6): 2453-2460

● **Absence of beta 7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine** *BLOOD*

Waldman, E., Lu, S. X., Hubbard, V. M., Kochman, A. A., Eng, J. M., Terwey, T. H., Muriglan, S. J., Kim, T. D., Heller, G., Murphy, G. F., Liu, C., Alpdogan, O., van den Brink, et al

2006; 107 (4): 1703-1711

● **Peripheral T cell apoptosis affects immune reconstitution after allogeneic BMT**

Alpdogan, O., McGoldrick, S., Lu, S., Patel, N., Suh, D., Smith, O. M., van den Brink, M. R.

CARDEN JENNINGS PUBL CO LTD.2006: 81

● **Adoptive transfer of in vitro generated T cell precursors improves T cell reconstitution and mediates graft-versus-tumor activity without graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients**

Zakrzewski, J. L., Kochman, A. A., Lu, S. X., Terwey, T., Kim, T. D., Hubbard, V. M., Muriglan, S. J., Suh, D., Cabrera-Perez, J., Heller, G., Zuniga-Pflucker, J. C., Alpdogan, O., van den Brink, et al

CARDEN JENNINGS PUBL CO LTD.2006: 82

● **T-cell signaling in allogeneic bone marrow transplantation**

Lu, S. X., Chow, M. Y., Hubbard, V. M., Suh, D. Y., Kim, T. D., Kochman, A., Zakrzewski, J., Cabrera-Perez, J., Alpdogan, O., van den Brink, M. R.

CARDEN JENNINGS PUBL CO LTD.2006: 24

- **Signaling profiles of T cells during allogeneic hematopoietic stem cell transplantation.**

Lu, S. X., Hubbard, V. M., Chow, M. Y., Kim, T. D., Suh, D. Y., Kochman, A., Zakrzewski, J., Cabrera-Perez, J., Alpdogan, O., van den Brink, M. M.
AMER SOC HEMATOLOGY.2005: 367A-368A

- **Adoptive transfer of in vitro generated T cell precursors enhances donor T cell reconstitution and graft-versus-tumor activity in allogeneic hematopoietic stem cell transplantation recipients.**

Zakrzewski, J. L., Kochman, A. A., Lu, S. X., Terwey, T. H., Kim, T. D., Hubbard, V. M., Muriglan, S. J., Suh, D., Cabrera-Perez, J., Radhakrishnan, R., Heller, G., Zuniga-Pflucker, J. C., Alpdogan, et al
AMER SOC HEMATOLOGY.2005: 23A

- **CCR2 is required for CD8-induced graft-versus-host disease** *BLOOD*

Terwey, T. H., Kim, T. D., Kochman, A. A., Hubbard, V. M., Lu, S., Zakrzewski, J. L., Ramirez-Montagut, T., Eng, J. M., Muriglan, S. J., Heller, G., Murphy, G. F., Liu, C., Budak-Alpdogan, et al
2005; 106 (9): 3322-3330

- **Adoptive transfer of in vitro-generated T cell precursors enhances posttransplant donor T cell reconstitution in recipients of an allogeneic hematopoietic stem cell transplantation**

Zakrzewski, J. L., Kochman, A., Muriglan, S. J., Lu, S., Kim, T. D., Zuniga-Pflucker, J. C., Alpdogan, O., van den Brink, M. R.
CARDEN JENNINGS PUBL CO LTD.2005: 4-5